Hisamitsu Pharmaceutical Co., Inc. logo

Hisamitsu Pharmaceutical Co., Inc. (4530)

Delisted
8 May 2026
JPX JPX
¥
6,040. 00
0
0%
¥
303.47B Market Cap
- P/E Ratio
0.76% Div Yield
679,000 Volume
- Eps
¥ 6,040
Previous Close
Day Range
6,040 6,050
Year Range
3,861 6,695
Want to track 4530 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

This company has been delisted from its primary exchange and is no longer publicly traded.
As a result, real-time price data, dividend updates, and corporate disclosures may no longer be available.

4530 Chart

Hisamitsu Pharmaceutical Co., Inc. (4530) FAQ

What does "Delisted" mean?

Hisamitsu Pharmaceutical Co., Inc. has been removed from the exchange and is no longer publicly traded.

What was the last recorded dividend?

The last recorded dividend was paid on Feb 26, 2026 in the amount of ¥60.00 per share.

How long did the company pay dividends?

The company paid dividends for 0 years prior to delisting.

Were there any stock splits?

No stock splits were recorded prior to delisting.

What was the last known trading price?

The stock last traded at ¥6,040.00 on May 08, 2026 before being delisted.

Hisamitsu Pharmaceutical Co., Inc. Profile

Specialty Retail Industry
Consumer Discretionary Sector
Kazuhide Nakatomi CEO
JPX Exchange
JP3784600003 ISIN
JP Country
2,769 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

Hisamitsu Pharmaceutical Co., Inc. is a distinguished pharmaceutical company based in Japan. Founded in 1847, it specializes in the manufacture and distribution of pharmaceutical products. The company is renowned for its production of external pain-relieving drugs and has achieved global reach, exporting its varied product range to approximately 40 countries and regions across Asia, the United States of America, and Europe. Hisamitsu Pharmaceutical Co., Inc. is headquartered in Tosu, Japan, marking its longevity and sustained relevance in the pharmaceutical industry with significant contributions to health and wellness worldwide.

Products and Services

  • External Pain-Relieving Drugs:

    Hisamitsu Pharmaceutical Co., Inc. offers a wide range of external pain-relieving products under brand names such as SALONPAS, NOBINOBI, SALONSIP, AIR, FEITAS, catering to various pain relief needs. These products are designed to provide relief from muscle and joint pains, utilizing topical technologies for consumer health care.

  • BUTENALOCK:

    A specially formulated medication for the treatment of athlete's foot, BUTENALOCK addresses the need for effective antifungal solutions, evidencing Hisamitsu's commitment to addressing a range of health care needs beyond pain relief.

  • ALLEGRA FX:

    This sinus medication is tailored for individuals suffering from allergies, providing relief from sinus pressure and symptoms associated with allergic reactions. ALLEGRA FX exemplifies Hisamitsu's endeavor to support those battling seasonal or chronic allergies.

  • Quasi-Drugs and Cosmetics:

    Hisamitsu's portfolio also includes a range of quasi-drugs and cosmetics, diversifying its offerings to meet the broader wellness and aesthetic needs of its customers, adhering to the high standards of safety and efficacy.

  • MOHRUS TAPE and MOHRUS PAP XR:

    These transdermal analgesic and anti-inflammatory drugs offer innovative solutions for pain management, allowing for the direct application of medication to the affected area through the skin, thus ensuring targeted relief and treatment.

  • Patches for Various Health Issues:

    Hisamitsu manufactures patches designed for the treatment of specific health conditions, including female hormone-related issues, asthma, and overactive bladders. These patches are part of Hisamitsu's specialized offerings that cater to the unique health care needs of individuals.

Contact Information

Address: 408 Tashirodaikan-machi
Phone: +81 3 5293 1700